Avadel Pharmaceuticals (AVDL) Non-Current Deferred Tax Liability (2016)
Historic Non-Current Deferred Tax Liability for Avadel Pharmaceuticals (AVDL) over the last 4 years, with Q1 2016 value amounting to $3.5 million.
- Avadel Pharmaceuticals' Non-Current Deferred Tax Liability fell 4018.42% to $3.5 million in Q1 2016 from the same period last year, while for Mar 2016 it was $3.5 million, marking a year-over-year decrease of 4018.42%. This contributed to the annual value of $2.8 million for FY2013, which is 8014.15% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Non-Current Deferred Tax Liability of $3.5 million as of Q1 2016, which was down 4018.42% from $6.1 million recorded in Q2 2015.
- Over the past 5 years, Avadel Pharmaceuticals' Non-Current Deferred Tax Liability peaked at $20.9 million during Q1 2012, and registered a low of $2.8 million during Q4 2013.
- Its 4-year average for Non-Current Deferred Tax Liability is $10.3 million, with a median of $8.3 million in 2013.
- Data for Avadel Pharmaceuticals' Non-Current Deferred Tax Liability shows a peak YoY increase of 3943.14% (in 2013) and a maximum YoY decrease of 8014.15% (in 2013) over the last 5 years.
- Quarter analysis of 4 years shows Avadel Pharmaceuticals' Non-Current Deferred Tax Liability stood at $14.1 million in 2012, then tumbled by 80.14% to $2.8 million in 2013, then skyrocketed by 116.36% to $6.1 million in 2015, then crashed by 42.23% to $3.5 million in 2016.
- Its Non-Current Deferred Tax Liability was $3.5 million in Q1 2016, compared to $6.1 million in Q2 2015 and $5.9 million in Q1 2015.